# Rallybio Completes Dosing of First Cohort in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
Canonical URL: https://biopharmsignal.com/news/RLYB/rallybio-completes-dosing-of-first-cohort-in-rlyb116-phase-1-confirmatory-pharmacokinetic-pharmacodynamic-study
Ticker: RLYB
Company: Rallybio
Source: Rallybio
Published: 2025-09-25 12:00 EST
Original Source URL: https://investors.rallybio.com
## Summary

– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic   and Enable Progression to Cohort 2 –    – Data Readouts for Completed Study Expected in 4Q 2025 – NEW HAVEN, Conn. --(BUSINESS WIRE)--Sep. 25, 2025-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology

## Article Body
– Interim Data Support Advancing RLYB116 as a Differentiated Therapeutic   and Enable Progression to Cohort 2 –    – Data Readouts for Completed Study Expected in 4Q 2025 – NEW HAVEN, Conn. --(BUSINESS WIRE)--Sep. 25, 2025-- Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology
## Recent Company News
- 2026-06-01 12:00 EST — [Rallybio Corporation and Avenzo Therapeutics Announce Merger Agreement to Advance Next-Generation Oncology Therapies and $215 Million Concurrent Private Placement](https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-avenzo-therapeutics-announce-merger-agreement-to-advance-next-generation-oncology-therapies-and-215-million-concurrent-private-placement) — Source: Rallybio
- 2026-03-02 13:00 EST — [Rallybio Corporation and Candid Therapeutics Announce Merger Agreement](https://biopharmsignal.com/news/RLYB/rallybio-corporation-and-candid-therapeutics-announce-merger-agreement) — Source: Rallybio
- 2026-02-17 13:00 EST — [Rallybio Announces Positive Data for RLYB116 Phase 1 Study Demonstrating Complete and Sustained Inhibition of Terminal Complement](https://biopharmsignal.com/news/RLYB/rallybio-announces-positive-data-for-rlyb116-phase-1-study-demonstrating-complete-and-sustained-inhibition-of-terminal-complement) — Source: Rallybio
- 2026-02-03 21:05 EST — [Rallybio Announces Reverse Stock Split of Common Stock](https://biopharmsignal.com/news/RLYB/rallybio-announces-reverse-stock-split-of-common-stock) — Source: Rallybio
- 2025-11-06 13:00 EST — [Rallybio Reports Third Quarter 2025 Financial Results and Provides Business Updates](https://biopharmsignal.com/news/RLYB/rallybio-reports-third-quarter-2025-financial-results-and-provides-business-updates) — Source: Rallybio
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)